Compare TotalEnergies SE (TTE) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TotalEnergies SE vs Viatris Inc — how do they compare? TotalEnergies SE trades at $87.56 (market cap $196.06B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: TotalEnergies SE is far larger — about 10.5× Viatris Inc's market cap, and TotalEnergies SE pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| TTE | VTRS | |
|---|---|---|
Market Cap | $196.06B | $18.69B |
Sector | Energy | Health |
52-Week High | $93.60 | $17.86 |
52-Week Low | $57.39 | $9.49 |
Enterprise Value | $227.06B | $30.80B |
Dividend Yield | 4.82% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TotalEnergies (TTE) trades at $87.49, down 0.53% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $94.00. The company reported mixed recent earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, while revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent strategic moves include acquiring Shell's European onshore renewables business and developing the Cronos gas field in Cyprus, signaling a shift toward integrated energy.
TTE presents a value opportunity with a low P/E of 11.01 and strong cash flow, but faces headwinds from declining revenue and regulatory climate litigation. The stock's upside is supported by analyst bullishness and dividend payments, yet investors must weigh energy transition execution risks against its current attractive valuation.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TotalEnergies SE
TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
